Johnson & Johnson $JNJ Stock Holdings Lowered by Interchange Capital Partners LLC

Key Points

• Interchange Capital Partners cut its Johnson & Johnson stake by 52.1% in the third quarter, selling 6,961 shares and retaining 6,407 shares valued at approximately $1.7 million.
• Despite the reduction, other major institutions increased their positions, and institutional investors collectively own 69.55% of J&J’s stock.
• J&J reported better-than-expected quarterly earnings and 5.9% year-over-year revenue growth, but shares trade near their 52-week high at a premium valuation. The company also declared a $1.34 quarterly dividend, representing a 2.0% yield.

Interchange Capital Partners LLC lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 52.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,407 shares of the company's stock after selling 6,961 shares during the period. Interchange Capital Partners LLC's holdings in Johnson & Johnson were worth $1,696,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Jupiter Topco LLC bought a new position in Johnson & Johnson in the second quarter worth approximately $1,967,399,000. Corient Private Wealth LP increased its holdings in Johnson & Johnson by 127.3% during the 2nd quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company's stock worth $1,539,292,000 after purchasing an additional 3,393,981 shares during the period. Wellington Management Group LLP raised its position in Johnson & Johnson by 12.5% during the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock valued at $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. Amundi raised its position in Johnson & Johnson by 17.5% during the 1st quarter. Amundi now owns 13,406,820 shares of the company's stock valued at $3,277,163,000 after purchasing an additional 2,001,139 shares in the last quarter. Finally, SEB Asset Management AB purchased a new stake in shares of Johnson & Johnson in the 1st quarter worth $314,468,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Icotyde, J&J’s oral plaque-psoriasis treatment, is reportedly gaining traction among U.S. dermatologists and being prescribed earlier in the treatment process. Strong adoption could support pharmaceutical growth and help offset declines in older products. Does Johnson & Johnson Have a New Edge in Plaque Psoriasis?
• Positive Sentiment: J&J presented 26 abstracts at TCT 2026 supporting the safety, efficacy and cost-effectiveness of its Impella heart pumps. The data may strengthen the long-term outlook for the MedTech portfolio despite recent weakness. Johnson & Johnson Presents Impella Data at TCT 2026
• Positive Sentiment: J&J continues to be highlighted as a dependable dividend stock, supported by more than five decades of annual payout increases. That income profile can provide downside support for long-term investors. Dividend Kings With 50-Plus Years of Payout Increases
• Neutral Sentiment: J&J’s recent performance has been strong, with shares reportedly up 42% over the past year, helped by progress toward resolving talc litigation and growth from newer medicines. Analysts are debating whether that advance has already priced in much of the improvement. Johnson & Johnson Is Up 42% in a Year
• Neutral Sentiment: Broker sentiment remains generally favorable, but the article questions how much weight investors should place on consensus recommendations as J&J trades near its 52-week high and at an elevated earnings multiple. Johnson & Johnson Broker Ratings
• Negative Sentiment: MedTech growth slowed in the third quarter because of international-market challenges and weakness at Abiomed. Investors may be concerned that a rebound in the fourth quarter will not fully offset the segment’s short-term disappointment. JNJ MedTech Segment Disappoints in Q3
• Negative Sentiment: Analysts see potential earnings pressure in 2027, while the market is already assigning a premium valuation after strong gains. That combination increases the risk of profit-taking if growth slows. Johnson & Johnson Strong Q3 Growth, but 2027 Could Test Earnings
• Negative Sentiment: Pomerantz announced an investigation into potential claims on behalf of J&J investors. Although such announcements do not establish wrongdoing, they add headline and litigation risk. Pomerantz Investor Investigation

Johnson & Johnson Stock Down 0.7%

Shares of Johnson & Johnson stock opened at $273.39 on Friday. The firm's 50 day moving average price is $265.74 and its 200-day moving average price is $246.94. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52-week low of $185.12 and a 52-week high of $282.02. The company has a market cap of $658.13 billion, a P/E ratio of 41.42, a PEG ratio of 2.70 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the previous year, the business posted $2.80 EPS. Johnson & Johnson's revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson's payout ratio is presently 81.21%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent research reports. Scotiabank reissued an "outperform" rating and set a $305.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. The Goldman Sachs Group reissued a "buy" rating and set a $282.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Guggenheim reissued a "buy" rating and issued a $287.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 7th. HSBC upped their target price on Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a report on Thursday, September 10th. Finally, Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $275.92.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 64,515 shares of company stock worth $17,271,766. Insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.